Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aspen Aerogels (ASPN) Cash & Equivalents (2016 - 2025)

Aspen Aerogels' Cash & Equivalents history spans 13 years, with the latest figure at $156.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 28.97% year-over-year to $156.9 million, compared with a TTM value of $156.9 million through Dec 2025, down 28.97%, and an annual FY2025 reading of $156.9 million, down 28.97% over the prior year.
  • Cash & Equivalents for Q4 2025 was $156.9 million at Aspen Aerogels, up from $150.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $281.3 million in Q4 2022, with the low at $17.2 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $140.7 million, with a median of $137.0 million recorded in 2023.
  • Year-over-year, Cash & Equivalents surged 1091.57% in 2022 and then crashed 51.09% in 2024.
  • Tracing ASPN's Cash & Equivalents over 5 years: stood at $76.6 million in 2021, then skyrocketed by 267.45% to $281.3 million in 2022, then plummeted by 50.34% to $139.7 million in 2023, then surged by 58.09% to $220.9 million in 2024, then dropped by 28.97% to $156.9 million in 2025.
  • Per Business Quant, the three most recent readings for ASPN's Cash & Equivalents are $156.9 million (Q4 2025), $150.7 million (Q3 2025), and $167.6 million (Q2 2025).